Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BPT567

Fusion protein · Immune activation, directed at PD-1 (PDCD1) and IL-18 receptor (IL18R1) · developed by Bright Peak Therapeutics

Phase 1 Most advanced trial (none active)

DRUG Developer

1 Registered trials

What is BPT567?

BPT567 is an immunocytokine composed of an anti-PD-1 antibody (lipustobart) conjugated to an IL-18 variant. It binds PD-1 on T-cells to block immune checkpoint signaling while the IL-18 component activates T-cells and NK cells, enhancing anti-tumor immunity. It is studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Fusion protein
Targets: PD-1 (PDCD1), IL-18 receptor (IL18R1)
Mechanism: Immune activation, directed at PD-1 (PDCD1) and IL-18 receptor (IL18R1)
Pathways: T-cell activation, NK cell activation, interferon-gamma secretion
Therapy area: Oncology
Developer: Bright Peak Therapeutics Inc (DRUG)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06779851	Phase 1	Advanced Solid Tumors	Terminated	DRUG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumors

Other drugs acting on PDCD1 / IL18R1

Berahyaluronidase Alfa and Pembrolizumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 Budigalimab Phase 2/3 Cadonilimab Early Phase 1 CDX-585 Phase 1 CTX-8371 Phase 1 Geptanolimab Phase 1/2 Ivonescimab Phase 3

More from Bright Peak Therapeutics

BC-101 Phase 1 BMB-101 Phase 2 YB-1113 Phase 1

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the DRUG page.

Follow DRUG, the company behind BPT567

See DRUG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DRUG catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z